By Amina Niasse (Reuters) -Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up ...

Key Points Hims & Hers is an exciting stock in the telehealth sector, but as a growth stock, it’s not for the faint of heart.

HIMS showcases outstanding financial strength. With just $63 million in debt against a market value of $13 billion, the ...

Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today ...

Hims & Hers leverages ZAVA's expertise to enter Europe's weight-loss market, boosting growth and profitability. Read what ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Hims & Hers Health Inc (NYSE:HIMS) stock fell 3.8% Tuesday after Eli Lilly and Company (NYSE:LLY) indicated it would not partner with telehealth firms selling copycat versions of weight-loss drugs, ...

Long Islanders, doctors and industry experts weigh in on medicines like Ozempic and Wegovy — how they work, what they ...

This fast growth has created some high expectations for Hims & Hers stock. It now has a price-to-earnings ratio (P/E) of 79, ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Hims said it is now selling "personalized" dosages of Wegovy, starting at around $165 a month, under rules allowing it for clinical reasons such as decreased side effects. Hims also sells ...